Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
Overview & Synopsis
Open access biomedical research article published in JTO Clin Res Rep.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study. |
|---|---|
| Author / Organization | Yan D, Liu C, Li X, Moore M, Xu R, Sanborn RE, Gadgeel SM, Millward M, Shi Z, Wang Y, Stazzone K, Chisamore MJ, Zhang L |
| Subject & Discipline | JTO Clin Res Rep |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-48345 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |